Chairman of The Antibody Series 2024

Dr. Mitchell Ho is a Senior Investigator and Deputy Chief of the Laboratory of Molecular Biology and Director of the Antibody Engineering Program at the Center for Cancer Research, NCI. Dr. Ho’s research encompasses investigating molecular mechanisms by which glypicans such as GPC1, GPC2 and GPC3 regulate Wnt signaling, as well as developing glypicans as cancer therapeutic targets.

His laboratory has constructed shark and camel single-domain antibody phage libraries to advance drug discovery. CAR-T cells developed in his laboratory are progressing towards clinical trials for the treatment of liver cancer, pediatric cancer and other malignancies. He is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and the founding Editor-in-Chief of Antibody Therapeutics (Oxford University Press). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign.